Modeling non-alcoholic fatty liver disease of different severity

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: One of the priority areas of modern medicine, which unites the interests of various specialists (therapists, cardiologists, gastroenterologists, endocrinologists), is the study of the pathogenesis and clinical manifestations of non-alcoholic fatty liver disease, which is widespread and of unconditional social significance. A search for non-alcoholic fatty liver disease adequate experimental model is of utmost importance for the studies of its etiology and pathogenesis. To understand all pathogenetic peculiarities of this pathology elaboration of hypercaloric hepatopathogenic diet rich in carbohydrates model is of utmost interest.

AIM: The aim of the study was to assess biochemical profile changes including antioxidant system significant markers in rat fructose-induced non-alcoholic fatty liver disease model.

MATERIALS AND METHODS: Two non-alcoholic fatty liver disease model versions were used: a light one — non-alcoholic steatosis and a severe variant — non-alcoholic steatohepatitis.

RESULTS: Both were characteristic of bilirubinemia, cholesterolemia, lipid peroxidation activation and antioxidation mechanisms suppression, cytolitic and cholestatic syndromes.

CONCLUSIONS: The extent of metabolic disorders proved to depend on non-alcoholic fatty liver disease model severity.

Full Text

Restricted Access

About the authors

Tatiana V. Brus

Saint Petersburg State Pediatric Medical University

Author for correspondence.
Email: bant.90@mail.ru
ORCID iD: 0000-0001-7468-8563
SPIN-code: 9597-4953

MD, PhD, Associate Professor, Department of Pathological Physiology with a Course of Immunopathology

Russian Federation, Saint Petersburg

Andrei G. Vasiliev

Saint Petersburg State Pediatric Medical University

Email: avas7@mail.ru
ORCID iD: 0000-0002-8539-7128

MD, PhD, Dr. Sci. (Medicine), Professor, Head of the Department of Pathological Physiology with a Course in Immunology

Russian Federation, Saint Petersburg

Anna V. Vasilieva

Saint Petersburg State Pediatric Medical University

Email: anvalvasileva@yandex.ru
SPIN-code: 5333-0144

Assistant Professor, Department of Pathological Physiology with a Course of Immunopathology

Russian Federation, Saint Petersburg

Sarng S. Pyurveev

Saint Petersburg State Pediatric Medical University; Institute of Experimental Medicine

Email: dr.purveev@gmail.com
ORCID iD: 0000-0002-4467-2269
SPIN-code: 5915-9767

MD, PhD, Assistant Professor, Department of Pathological Physiology with the Course of Immunopathology, Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation; Research Associate, Department of Neuropharmacology, Institute of Experimental Medicine

Russian Federation, Saint Petersburg; Saint Petersburg

Rodion V. Korablev

Saint Petersburg State Pediatric Medical University

Email: rodion.korablev@gmail.com
SPIN-code: 4969-6038

MD, PhD, Associate Professor, Department of Pathological Physiology with a Course of Immunopathology

Russian Federation, Saint Petersburg

Anastasiya V. Bannova

V.I. Vernadsky Crimean Federal University

Email: bannova06@list.ru
ORCID iD: 0009-0007-6867-9477
SPIN-code: 2034-8324

2nd year student of 1st medical faculty, S.I. Georgievsky Order of the Red Banner of Labor Medical Institute

Russian Federation, Simferopol

Irina I. Mogileva

Saint Petersburg State Pediatric Medical University

Email: flan43@mail.ru

Associate Professor, Head of the Department of Foreign Languages with courses in Russian and Latin

Russian Federation, Saint Petersburg

Mariya Yu. Daineko

Saint Petersburg State Pediatric Medical University

Email: aspirantura@gpmu.org
SPIN-code: 4188-3230

PhD, Associate Professor, Head of the Department of Foreign Languages with courses in Russian and Latin

Russian Federation, Saint Petersburg

Vladimir A. Evgrafov

Saint Petersburg State Pediatric Medical University

Email: psh_k@mail.ru

MD, PhD, Associate Professor, Department of Anesthesiology, Resuscitation and Emergency Pediatrics named after Professor V.I. Gordeev

Russian Federation, Saint Petersburg

Natalia A. Nudelman

Saint Petersburg State Pediatric Medical University

Email: bant.90@mail.ru
SPIN-code: 5386-8740

Senior Lecturer, Department of Foreign Languages with courses in Russian and Latin

Russian Federation, Saint Petersburg

Iren L. Galfanovich

Saint Petersburg State Pediatric Medical University

Email: bant.90@mail.ru

Senior Lecturer, Department of Foreign Languages with courses in Russian and Latin

Russian Federation, Saint Petersburg

Lyudmila M. Tyumina

Saint Petersburg State Pediatric Medical University

Email: bant.90@mail.ru
SPIN-code: 8706-0338

Senior Lecturer, Department of Foreign Languages with courses in Russian and Latin

Russian Federation, Saint Petersburg

References

  1. Yoneda M, Imajo K, Takahashi H, et al. Rodent models of nonalcoholic fatty liver disease (non-alcoholic steatohepatiti). Int J Mol Sci. 2013;14(11):21833–21857. doi: 10.3390/ijms141121833
  2. Chercashina EA, Petrenco LV, Evstigneeva AYu. Non-alcoholic fatty liver disease: pathogenesis, diagnostics, treatment. Ulyanovsk Medical and Biological Journal. 2014;(1):35–46. EDN: QKICIT
  3. Brus TV, Vasiliev AG, Trashkov AP. The main biochemical markers of non-alcoholic fatty liver disease of various severity (experimental study). Pathological physiology and experimental therapy. 2022;66(1):44–51 (In Russ.) doi: 10.25557/0031-2991.2022.01.44-51 EDN: OOMRKU
  4. Brus TV, Kalinina AA, Bannova AA, et al. Influence of non-alcoholic fatty liver disease on reproductive function in an experiment. Pediatrician (St. Petersburg). 2024;15(1):37–44. doi: 10.17816/PED15137-44 EDN: HXADVS
  5. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:161–166. doi: 10.21037/tgh.2019.09.08
  6. Drapkina OM, Gatsolayeva DS, Ivashkin VT. Nonalcoholic fatty liver disease as a component of metabolic syndrome. Russian medical news. 2010;15(2):72–78. EDN: MLHZDB
  7. Brunt EM, Wong VW, Nobili V, et al. Non-alcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080. doi: 10.1038/nrdp.2015.80
  8. Rinella ME. Non-alcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273. doi: 10.1001/jama.2015.5370
  9. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20(2):205–214. doi: 10.1016/j.cld.2015.10.001
  10. Mareev VYu, Fomin IV, Ageev FT, et al. Chronic heart failure (CHF). Journal of Heart Failure. 2017;18(1):3–40. doi: 10.18087/rhfj.2017.1.2346. EDN: YHVIOF
  11. Schwarz JM, Noworolski SM, Wen MJ, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metabol. 2015;100(6):2434–2442. doi: 10.1210/jc.2014-3678
  12. Komshilova KA, Troshina EA. Obesity and non-alcoholic fatty liver disease: metabolic risks and their correction. Obesity and metabolism. 2015;12(2):35–39. doi: 10.14341/omet2015234-38 EDN: UHHUWX
  13. Trashkov AP, Brus TV, Vasiliev AG, et al. Red blood indicators’ dynamics in rats with non-alcoholic fatty liver disease and possibilities of its correction. Clinical Pathophysiology. 2017;23(3):66–72. EDN: YPKUDT
  14. Нaddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of non-alcoholic steatohepatitis. Evid Based Complement Alternat Med. 2011;2011:nep164. doi: 10.1093/ecam/nep164
  15. Lieber CS, Leo MA, Mak KM, et al. Model of non-alcoholic steatohepatitis. Am J Clin Nutrit. 2004;79(3):502–509. doi: 10.1093/ajcn/79.3.502
  16. Younossi ZM. Non-alcoholic fatty liver disease — a global public health perspective. J Hepatol. 2019;70(3):531–544. doi: 10.1016/j.jhep.2018.10.033
  17. Ackerman Z, Oron-Herman M, Grozovski M, et al. Fructose-induced fatty liver disease hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005;45(5):1012–1018. doi: 10.1161/01.HYP.0000164570.20420.67
  18. Flessa CM, Nasiri-Ansari N, Kyrou I, et al. Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD). Research. International Journal of Molecular Sciences. 2022;23(24):15791. doi: 10.3390/ijms232415791
  19. Winkler TW, Gunther F, Hollerer S, et al. A joint view on genetic variants for adiposity differentiates subtypes with distinct metabolic implications. Nat Commun. 2018;9(1):1946. doi: 10.1038/s41467-018-04124-9
  20. Asgharpour A, Cazanave SC, Pacana T, et al A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65(3):579–588. doi: 10.1016/j.jhep.2016.05.005
  21. Baumgardner J, Shankar K, Hennings L, et al. A new model for non-alcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):27–38. doi: 10.1152/ajpgi.00296.2007
  22. Dela Peña A, Leclercq I, Field J, et al. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology. 2005;129(5):1663–1674. doi: 10.1053/j.gastro.2005.09.004
  23. Fan J-G, Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int. 2009;8(3):233–240.
  24. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87(1):1–16. doi: 10.1111/j.0959-9673.2006.00465.x
  25. Larter C, Yeh M. Animal models of non-alcoholic steatohepatitis: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008;23(11):1635–1648. doi: 10.1111/j.1440-1746.2008.05543.x
  26. Wang Y, Ausman L, Greenberg A, et al. Non-alcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int J Cancer. 2009;124(3):540–546. doi: 10.1002/ijc.23995
  27. Gao D, Wei C, Chen L, et al. Oxidative deoxyribonucleic acid. damage and deoxyribonucleic acid repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;287(5):1070–1077. doi: 10.1152/ajpgi.00228.2004
  28. Da Silva Pereira EN, Silvares RR, Ilaquita Flores EE, et al. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease. PLOS One. 2017;6(12):0179654. doi: 10.1371/journal.pone.0179654

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Total cholesterol (TC), triacylglycerides (TAG), glucose (Glu) and homocysteine (HC) level changes (mmol/L) in rats with liver steatosis and steatohepatitis.

Download (127KB)
Indexing metadata
3. Fig. 2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDG) level changes (IU/l) in rats with liver steatosis and steatohepatitis.

Download (154KB)
Indexing metadata
4. Fig. 3. Histological changes in “Liver steatosis”: a, hematoxylin-eosin 10×; b, hematoxylin-eosin 40×.

Download (367KB)
Indexing metadata
5. Fig. 4. Histological changes in “Steatohepatitis”: a, hematoxylin-eosin, 10×; b, hematoxylin-eosin, 40×.

Download (356KB)
Indexing metadata
6. Fig. 5. Histological changes in Control group: a, hematoxylin-eosin, 10×; b, hematoxylin-eosin, 40×.

Download (294KB)
Indexing metadata

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.